Talphera asked the FDA to close enrollment by December 31, 2026, citing enrollment above 75% and primary-endpoint power above 80%. It expects FDA feedback by year-end, data within four to six weeks, and peak U.S. sales above $200 million.
TLPH · Talphera, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 61%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Talphera, Inc. may offer up to $150,000,000 of common stock, preferred stock, debt securities and warrants from time to time, with proceeds intended for working capital, general corporate purposes and debt payments.
Talphera reported a net loss of (10,886) in thousands for the nine months ended September 30, 2026; recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.
Talphera, Inc. seeks FDA feedback on closing NEPHRO CRRT enrollment as of December 31, 2026, even with fewer than 70 patients; enrollment provides more than 80% statistical power. Cash and investments were $14.2 million at September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Updated research raised nafamostat's estimated peak CRRT sales to more than $200 million, while current study power supports a potential PMA filing and financing is expected to fund operations through at least a potential 2027 approval. Enrollment has slowed sharply and operating expenses increased; if FDA does not agree to early closure, enrollment would continue to 70 patients, and clinical studies may not be fully enrolled or completed or confirm assumed characteristics.
- + Updated market research increased nafamostat's estimated peak sales for CRRT to more than $200 million. new
- + Current NEPHRO enrollment is believed sufficient for a PMA filing, with more than 80% statistical power for the primary endpoint. new
- + Cash and conditional financing tranches are expected to fund the company through at least a potential PMA approval in 2027. new
- + Clinical-outcomes evidence may support growth of the overall CRRT market. new
- + Updated draft kidney-disease guidelines recognize nefamostat as an alternative anticoagulant when citrate cannot be used. new
- + Third-quarter net loss attributable to common shareholders improved to $4.0 million, or $0.05 per share, from $4.4 million, or $0.11 per share. new
- − NEPHRO enrollment has slowed unexpectedly because of fewer qualifying patients. new
- − The number of patients consented and enrolled dropped 85% to 90% versus the same period in 2025. new
- − Cash operating expenses increased to $3.8 million from $3.3 million, driven by development and pre-launch preparation spending. new
- − If the FDA rejects the proposed early closure, enrollment would continue to 70 patients. new
- − Clinical studies may not be fully enrolled or completed and may not confirm assumed safety or efficacy characteristics. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Combined R&D and SG&A expenses non-GAAP | 3.8M | third quarter of 2026 | — |
| Operating expenses (non-GAAP) non-GAAP | 11.26M | Nine Months Ended September 30, 2026 | — |
| Patients enrolled | 75% | To date | — |
| Statistical power for primary endpoint | 80% | To date | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLPH
this stock
Talphera, Inc.
|
$40.80M | -31.1% | -73.1% | — | 2.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$69.55B | +39.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.29B | +4.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.77B | +25.7% | +4.3% | 89.2 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 15
Talphera reported a net loss of (10,886) in thousands for the nine months ended September 30, 2026; recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLPH | -13.3% | -27.3% | +0.7% | -23.8% | -31.1% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -4.8% | -18.1% | +9.9% | -15.1% | -32.3% |